CN116254190A - Lactobacillus paracasei subspecies and application thereof - Google Patents
Lactobacillus paracasei subspecies and application thereof Download PDFInfo
- Publication number
- CN116254190A CN116254190A CN202211447286.9A CN202211447286A CN116254190A CN 116254190 A CN116254190 A CN 116254190A CN 202211447286 A CN202211447286 A CN 202211447286A CN 116254190 A CN116254190 A CN 116254190A
- Authority
- CN
- China
- Prior art keywords
- subspecies
- lactobacillus paracasei
- paracasei
- lactobacillus
- paracasei subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a Lactobacillus paracasei subspecies @Lacticaseibacillus paracasei subsp.paracasei) JY092, subspecies of Lactobacillus paracasei were deposited with the Guangdong province microorganism strain collection, with a date of deposition of 2022, month 08 and 20, and with a deposit number of GDMCC NO:62721. the invention also discloses application of the lactobacillus paracasei subspecies in preparing medicines for treating hyperuricemia and/or gout. The lactobacillus paracasei subspecies provided by the invention have high-efficiency degradation effect on inosine and guanosine, have good acid resistance, and can survive in gastric juice; and has the capability of tolerating the normal bile concentration of a human body. The Lactobacillus paracasei subspecies can smoothly reach intestinal tract and survive in intestinal tractThe key of the probiotics function, JY092 is suitable for taking after meal so as to make it better exert uric acid reducing function.
Description
Technical Field
The invention relates to lactobacillus paracasei subspecies and application thereof, and belongs to the technical field of microorganisms.
Background
Hyperuricemia is a metabolic disease caused by purine metabolic disorders. When uric acid production is increased or excretion is reduced in human body, serum uric acid level is beyond normal range, namely hyperuricemia is easy to occur. Hyperuricemia is not only a biochemical basis for gout incidence, but also is more likely to cause chronic diseases such as atherosclerosis, obesity, uric acid nephropathy and the like, thereby forming a potential threat to the life safety of human bodies.
The prevention and treatment of hyperuricemia mainly comprises drug treatment and reduction of purine substance intake. The medicines for treating hyperuricemia commonly used in clinic mainly comprise allopurinol, benzbromarone and the like, and the allopurinol belongs to an inhibitor of xanthine oxidase which is a key enzyme for synthesizing uric acid, but clinical researches show that the medicines have side effects of damaging kidneys, causing allergy and the like; tribromone can inhibit reabsorption of renal urate, but is not widely used due to its side effects on liver and kidneys. And high purine foods are of various kinds, such as red meat, seafood, liver, poultry, beer, etc., so that it will be difficult to maintain the nutrient balance provided by the foods by controlling the diet. Because the pathogenesis of hyperuricemia is complex, not only medicines are required to be taken during treatment, but also diet is required to be strictly controlled, so that the treatment compliance of patients is not high, and the intake of purine substances can cause negative factors such as nutrient deficiency based on side effects and diet control of long-term medicine treatment.
Therefore, there is a need for a safe and effective subspecies of lactobacillus paracasei with uric acid reducing effect and application thereof.
Disclosure of Invention
The invention aims to provide JY092 of Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) with uric acid reducing effect.
Meanwhile, the invention provides an application of the Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) JY092 in preparing medicaments for treating hyperuricemia.
In order to solve the technical problems, the invention adopts the following technical scheme:
application of Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) JY092 with uric acid reducing effect in preparing medicines for treating hyperuricemia and/or gout.
The Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) JY092 was derived from a Tibetan traditional fermented dairy product, and the strain was analyzed by sequencing, and the 16S rDNA sequence thereof was as follows (SEQ ID NO: 1):
GAGGAGACTGCGGCGTGCTATACATGCAAGTCGAACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAACATGGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACATTTGGAAACAGATGCTAATACCGCATAGATCCAAGAACCGCATGGTTCTTGGCTGAAAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAATGGCTCACCAAGGCGATGATACGTAGCCGAACTGAGAGGTTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACTCTGTTGTTGGAGAAGAATGGTCGGCAGAGTAACTGTTGTCGGCGTGACGGTATCCAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCCTCGGCTTAACCGAGGAAGCGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCATGCCGTAAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCCCTTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGACCGCAAGGTTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCCTTCGGGGGCAAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATGACTAGTTGCCAGCATTTAGTTGGGCACTCTAGTAAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGAGGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTAACACCCGAAGCCGGTGGCGTAACCCTTTTAGGGAGCGAGCCGTCTAAGTGACAAAGTA the sequencing of the sequences in NCBI database for nucleic acid sequence alignment, the results show that the strain is Lactobacillus paracasei subspecies, named Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) JY092, deposited in the Guangdong province microorganism strain collection, guangzhou, with a date of deposition of 2022, month 08 and 20, and a deposit number of GDMCC NO:62721. colony protrusions of the Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) JY092 (hereinafter referred to as JY 092) on the MRS culture medium have smooth, round, moist, white and opaque surfaces, and the diameter is 0.7-1.5 mm.
Screening, identification, cultivation, observation and preservation of lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paramasei) JY092 were as follows:
1. screening
Taking 1g of traditional fermented dairy product from Tibetan area, coating the product in MRS solid culture medium (containing rapid screening) after gradient dilution, culturing the product in anaerobic environment at 37 ℃ for 48 hours, and observing and recording colony morphology; picking out white bacterial colony with wet surface and bulges, scribing on MRS solid culture medium, purifying and culturing under anaerobic condition at 37 ℃ and repeating the operation for 3 times to obtain purified single bacterial colony; single colonies were picked and streaked on MRS solid medium and anaerobically cultured at 37℃for 48h.
2. Authentication
Extracting genome of the strain obtained by screening, amplifying and sequencing 16S rDNA of the strain (the nucleotide sequence of the amplified 16S rDNA is shown as SEQ ID NO. 1), and comparing the obtained sequence with a nucleic acid sequence in NCBI-Blast, wherein the result shows that the strain is lactobacillus paracasei subspecies, and is named as lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paralasei) JY092.
Among them, the primers used for 16S rDNA amplification were as follows:
27F upstream primer: 5'-AGTCTCTGATCATGCCTCAG-3';
1492R downstream primer: 5'-AAGGAGGTGCTCCAGCC-3';
the 16S rDNA amplification procedure was as follows:
95 ℃ for 5min;35 cycles (95 ℃ 30s;55 ℃ 30s;72 ℃ 2 min); and at 72℃for 10min.
4. Preservation of
Selecting single colony of Lactobacillus paracasei subspecies (Lacticaseibacillus paracasei subsp. Paracasei) JY092, inoculating into MRS liquid culture medium, and culturing at 37deg.C under anaerobic condition for 18 hr to obtain bacterial liquid; adding sterilized 80% (v/v) glycerol into the obtained bacterial liquid, mixing, and storing in glycerol pipe at-80deg.C. Meanwhile, the subspecies of the lactobacillus paracasei are preserved in the microorganism strain collection center of Guangdong province, guangzhou, wherein the preservation date is 2022, 8 and 20, and the preservation number is: GDMCC NO:62721.
the viable count of the lactobacillus paracasei subspecies is not less than 10 7 cfu/mL。
The medicine contains pharmaceutically acceptable auxiliary materials.
The invention has the following beneficial effects:
the lactobacillus paracasei subspecies provided by the invention have high-efficiency degradation effect on inosine and guanosine, have good acid resistance, and can survive in gastric juice; and has the capability of tolerating the normal bile concentration of a human body.
The Lactobacillus paracasei subspecies provided by the invention can smoothly reach the intestinal tract and survive in the intestinal tract, which is the key of playing a probiotic function, and JY092 is suitable for being taken after meals so as to enable the Lactobacillus paracasei subspecies to better play the uric acid reducing function.
The lactobacillus paracasei subspecies provided by the invention also have high-efficiency degradation capability on purine nucleosides in satiety artificial intestinal juice.
Drawings
FIG. 1 is a graph showing the acid resistance results of JY092 in the present invention;
FIG. 2 is a graph showing the results of JY092 bile salt resistance in the present invention;
FIG. 3 is a graph showing the tolerance results of JY092 artificial digestive juice in the present invention;
FIG. 4 is a graph showing the results of detection of uric acid in serum of mice in accordance with the present invention;
FIG. 5 is a graph showing the results of detection of uric acid in urine of mice in accordance with the present invention;
FIG. 6 is a graph of colonies of Lactobacillus paracasei subspecies of the present invention.
Detailed Description
The invention will be further described with reference to the accompanying drawings.
In this example, lactic acid bacteria with high-efficiency degradation effect on inosine and guanosine are screened out of several lactic acid bacteria in vitro by using a high performance liquid chromatography, and the strain (as shown in fig. 6, bacterial colony protrusion of the strain JY092 on MRS culture medium, smooth, round, moist, white and opaque with the diameter of 0.7-1.5 mm) is subjected to environmental tolerance evaluation such as acid resistance, bile salt resistance and artificial gastrointestinal fluid to determine the tolerance characteristics of the strain, thereby verifying the colonization condition of the strain in intestinal tract and whether the strain can play its role in gastrointestinal tract. The embodiment effectively enriches the strain library of uric acid reducing lactic acid bacteria and provides a safe and effective new strain for the treatment application of hyperuricemia, gout and metabolic diseases related to uric acid.
(1) Screening of high-efficiency degradation nucleoside lactobacillus:
inosine and guanosine were detected using a High Performance Liquid Chromatography (HPLC) system. 39.9mg of inosine and 37.8mg of guanosine were dissolved in 100mL of 0.1mol/L K, respectively 3 PO 4 In the solution, 1.41mmol/L guanosine and inosine solutions were prepared, while 0.282mmol/L, 0.564mmol/L, 0.846mmol/L, and 1.128mmol/L guanosine and inosine solutions were prepared. After filtration through a 0.22 μm aqueous filter, the solutions were respectively injected into a high performance liquid chromatography apparatus equipped with an ultraviolet wavelength detector and a chromatographic column. The chromatographic column model is E clipse Plus C 18 (50X 4.6 mm), flow rate: 1mL/min, mobile phase was 100% 30mmol/L KH 2 PO 4 -K 2 HPO 4 Solution, set time: 30min. Inosine and guanosine levels were measured at a wavelength of 260 nm. Linear regression was performed with the concentration of the solution and the peak area, and quantification was performed by a standard curve method.
KH 2 PO 4 -K 2 HPO 4 The preparation method of the solution comprises the following steps: 4.0827g KH 2 PO 4 And 5.2254g K 2 HPO 4 Dissolved in 1LddH 2 O.
Results: in the embodiment, the nucleoside utilization rate is calculated based on a chromatogram and a standard curve of 10 strains of lactic acid bacteria, and the 10 strains are found to have certain nucleoside utilization capacity, but different strains have obvious difference in nucleoside utilization capacity. Table 1 shows strains with higher degradation capacity, wherein JY092 had higher guanosine and inosine degradation rates.
TABLE 1 degradation rates of guanosine and inosine by different strains
(2) Acid resistance of the strain:
and centrifuging the activated thalli for 5min at 6000r/min and 4 ℃. After washing 2-3 times with PBS, the plates were subjected to viable count after incubation at 37℃for 1h,2h,3h and 4h in MRS broth medium with pH 6.2 (control), 2, 3 and 4, respectively.
MRS broth medium composition: 10.0g/L peptone, 8.0g/L beef extract powder, 4.0g/L yeast extract powder, 20.0g/L glucose, 2.0g/L dipotassium hydrogen phosphate, 2.0g/L dipotassium hydrogen citrate, 5.0g/L sodium acetate, 0.2g/L magnesium sulfate, 0.04g/L manganese sulfate and 1.0g/L Tween 80.
The preparation process comprises the following steps: 52.24g of MRS powder is taken and dissolved in 1000mL of distilled water by heating, and the mixture is autoclaved at 120 ℃ for 15 minutes for standby.
Results: since good acid tolerance and bile salt tolerance are the preconditions that lactic acid bacteria can exert physiological functions in the human body, it is necessary to examine acid tolerance and bile salt tolerance of the strain to be screened. The pH of human gastric acid is generally 1.5-2 when it is used in fasting or edible acidic foods, while the pH can reach 4-5 when it is used in basic foods, and generally ph=3. Survival of JY092 under different acidic conditions As shown in FIG. 1, the acidic environment with pH=2 survived the fungusThe effect of the rate is large, but the survival number of the bacteria is always 10 within 4 hours under the condition of pH 3 7 Above cfu/mL, the bacterium has good acid resistance and can survive in gastric juice.
(3) Bile salt tolerance of the strain:
and centrifuging the activated thalli for 5min at 6000r/min and 4 ℃. After washing 2-3 times with PBS, plating was performed in MRS broth medium at 0% (control group) and 0.3% bile salt concentration, respectively, after incubation at 37℃for 1h,2h,3h and 4h, plate viable count was performed.
Results: the mass fraction of the normal bile of the human body is 0.3 percent. JY092 can still reach 10 after being cultured for 1h,2h,3h and 4h in MRS culture medium with the mass fraction of bile salt of 0.3 percent at 37 DEG C 7 cfu/mL and above, and remain relatively stable, and the experimental results are shown in figure 2, which shows that the bacteria have the capability of tolerating normal bile concentration of human bodies.
(4) Tolerance of the strain to artificial gastrointestinal fluids:
simulating gastric juice: the concentration is 3g/L pepsin, the pH is adjusted to 3.0, and the filter sterilization is carried out for standby.
Simulation of intestinal juice: trypsin at a concentration of 1g/L was added, followed by 0.3% bile salts, and the pH was adjusted to 7.0.
The strain is activated for two generations, at the end of the logarithmic growth phase, the strain is centrifuged for 10min at 6000r/min at 4 ℃, bacterial precipitate is collected, washed for 2 times by PBS and resuspended in simulated gastric fluid, after anaerobic culture for 2h at 37 ℃, transferred to simulated intestinal fluid, after culture for 3h at 37 ℃, viable bacteria count is performed by using a dilution coating plate method.
Results: as can be seen from FIG. 3, the live bacteria of JY092 only have a 1X 10 number of live bacteria in the fasting state 4 About cfu/mL, but in the satiety state, the live bacterial count of JY092 is 1X 10 7 Above cfu/mL, the number of the bacterial cells required by the active lactobacillus to exert the probiotic effect in the intestinal tract in the prior art is obviously higher than that of the active lactobacillus (1 multiplied by 10 6 cfu/mL). The JY092 is suitable for being taken after meal so as to enable the JY092 to better play the uric acid reducing function. The control experiment in fig. 3 is a blank with PBS buffer only.
In this example, only artificial gastrointestinal fluid is used in the fasting state, no nutrient solution is used, and nutrient solution is used in the satiety state.
The nutrient solution comprises 1.0g/L of arabinogalactan, 2.0g/L of gelatin, 1.0g/L of xylan, 3.0g/L of potato starch, 0.4g/L of glucose, 3.0g/L of yeast powder, 1.0g/L of peptone, 4.0g/L, L-cysteine and 0.5g/L of mucin. The preparation process comprises the following steps: dissolving the solute in the above formula in 1000mL distilled water to obtain the final product.
(5) Degradation rate of the strain on nucleoside in simulated artificial gastrointestinal fluid environment:
1mL of the cell culture solution was collected by centrifugation, washed 2 times with PBS, and the cells were suspended in 900. Mu.L of a saturated artificial intestinal solution and PBS buffer solution, which had both inosine and guanosine concentrations of 1.41mmol/L, and reacted at 37℃for 1 hour, after which the degradation rates of inosine and guanosine were measured, and the control group was not supplemented with cells.
Results: the small intestine is the place where the lactic acid bacteria degrade the purine nucleosides, so the present example examined the degradation ability of JY092 on purine nucleosides in the satiety artificial intestinal juice. As can be seen from table 2, JY092 also exhibited high-efficiency inosine and guanosine degrading ability in the saturated artificial intestinal fluid as in the buffer (table 1).
TABLE 2 simulation of degradation rate of JY092 on guanosine and inosine under intestinal tract
Animal experiment:
50 male C57BL/6 mice, weighing 24-29g, were randomly divided into 5 groups: normal group, model group, low dose fungus powder group (10) 7 cfu/mL), medium dose fungus powder group (10) 8 cfu/mL), high dose fungus powder group (10) 9 cfu/mL), 10 mice per group, maintained at about 24 ℃ at room temperature, with free water during the experiment, all mice were acclimatized for one week; modeling period: normal groups were fed with normal feed, the remaining groups were fed with high purine mice and potassium oxazinate (injected at 400mg/100g body weight) for 7 days, and the blood uric acid level of each group of mice was determined to determine whether modeling was successful; treatment period: all mice were givenThe normal feed is fed, the normal group and the model group are irrigated with 0.5mL of PBS buffer solution, and the low, medium and high dose bacterial powder components are respectively irrigated with 0.5mL of bacterial suspension for 7 days. Blood and urine from each group of mice were collected after the end of the experiment to determine uric acid levels. Determination of serum uric acid in mice: the blood is naturally coagulated at room temperature for 10-20 min, centrifuged at 2000-3000r/min for 20 min, the supernatant is carefully collected, if precipitation occurs, and centrifuged again. Detection was performed using a mouse Uric Acid (UA) ELISA kit. As can be seen from FIG. 4, the gastric lavage powder reduced uric acid levels in mice blood, and as the concentration of bacteria increased, uric acid levels decreased more significantly, and the medium-dose bacteria concentration (10 8 cfu/mL) and high-dose bacteria concentration (10) 9 cfu/mL) and model group were significantly different (P<0.05). Urine uric acid assay in mice: mouse urine was collected with a sterile tube, centrifuged at 2000-3000r/min for 20 min, the supernatant carefully collected, if a precipitate formed, and centrifuged again. Detection was performed using a mouse Uric Acid (UA) ELISA kit. As can be seen from FIG. 5, the gastric lavage powder reduced uric acid levels in the urine of mice, with the uric acid levels decreasing more significantly with increasing bacterial concentration, and with medium-dose bacterial concentrations (10 8 cfu/mL) and model group were significantly different (P<0.05 High dose bacteria concentration (10) 9 cfu/mL) was very different from model group (P)<0.01)。
In summary, the lactobacillus paracasei subspecies of the present invention can treat hyperuricemia and/or gout.
The foregoing is only a preferred embodiment of the invention, it being noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the present invention, and such modifications and adaptations are intended to be comprehended within the scope of the invention.
Claims (6)
1. A subspecies of lactobacillus paracasei (Lacticaseibacillus paracasei subsp.paracasei) JY092, wherein said subspecies of lactobacillus paracasei are deposited with the collection of microorganism strains in the cantonese province, guangzhou, at a date of 2022, 20 months, under a deposit number GDMCC NO:62721.
2. a lactobacillus paracasei subspecies according to claim 1, characterized in that the nucleic acid sequence of the 16S rDNA of the lactobacillus paracasei subspecies is shown in SEQ ID No. 1.
3. A lactobacillus paracasei subspecies according to claim 1, characterized in that the colony protrusions of the lactobacillus paracasei subspecies on the MRS medium are smooth, round, moist, white opaque with a diameter of 0.7-1.5 mm.
4. Use of a subspecies lactobacillus paracasei according to any of claims 1 to 3 for the preparation of a medicament for the treatment of hyperuricemia and/or gout.
5. The use according to claim 4, wherein the viable count of the Lactobacillus paracasei subspecies in the pharmaceutical product is not less than 10 7 cfu/mL。
6. The use according to claim 4, wherein the medicament comprises pharmaceutically acceptable excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211447286.9A CN116254190A (en) | 2022-11-18 | 2022-11-18 | Lactobacillus paracasei subspecies and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211447286.9A CN116254190A (en) | 2022-11-18 | 2022-11-18 | Lactobacillus paracasei subspecies and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116254190A true CN116254190A (en) | 2023-06-13 |
Family
ID=86686888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211447286.9A Pending CN116254190A (en) | 2022-11-18 | 2022-11-18 | Lactobacillus paracasei subspecies and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116254190A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116622593A (en) * | 2023-07-21 | 2023-08-22 | 中国农业科学院农产品加工研究所 | Lactobacillus paracasei for fermentation and fermentation process for preparing wind-resistant acid-discharging ferment by same |
| CN117025456A (en) * | 2023-07-31 | 2023-11-10 | 广西爱生生命科技有限公司 | Lactobacillus paracasei A21151 with blood uric acid reducing and anti-inflammatory effects and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102108337A (en) * | 2010-07-28 | 2011-06-29 | 江南大学 | Lactobacillus casei and application thereof |
| CN110878270A (en) * | 2019-12-21 | 2020-03-13 | 福建省农业科学院农业工程技术研究所 | Lactobacillus paracasei subspecies paracasei and application thereof |
| CN112899190A (en) * | 2021-02-02 | 2021-06-04 | 生合生物科技（扬州）有限公司 | Lactobacillus paracasei LPC48 with function of preventing and/or improving gout and application thereof |
| CN113913346A (en) * | 2021-11-22 | 2022-01-11 | 江南大学 | Lactobacillus paracasei JN-1 and application thereof |
| CN115232768A (en) * | 2022-07-22 | 2022-10-25 | 江南大学 | Lactobacillus paracasei JN-8 and application thereof |
-
2022
- 2022-11-18 CN CN202211447286.9A patent/CN116254190A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102108337A (en) * | 2010-07-28 | 2011-06-29 | 江南大学 | Lactobacillus casei and application thereof |
| CN110878270A (en) * | 2019-12-21 | 2020-03-13 | 福建省农业科学院农业工程技术研究所 | Lactobacillus paracasei subspecies paracasei and application thereof |
| CN112899190A (en) * | 2021-02-02 | 2021-06-04 | 生合生物科技（扬州）有限公司 | Lactobacillus paracasei LPC48 with function of preventing and/or improving gout and application thereof |
| CN113913346A (en) * | 2021-11-22 | 2022-01-11 | 江南大学 | Lactobacillus paracasei JN-1 and application thereof |
| CN115232768A (en) * | 2022-07-22 | 2022-10-25 | 江南大学 | Lactobacillus paracasei JN-8 and application thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116622593A (en) * | 2023-07-21 | 2023-08-22 | 中国农业科学院农产品加工研究所 | Lactobacillus paracasei for fermentation and fermentation process for preparing wind-resistant acid-discharging ferment by same |
| CN116622593B (en) * | 2023-07-21 | 2023-10-20 | 中国农业科学院农产品加工研究所 | Lactobacillus paracasei for fermentation and fermentation process for preparing wind-resistant acid-discharging ferment by same |
| CN117025456A (en) * | 2023-07-31 | 2023-11-10 | 广西爱生生命科技有限公司 | Lactobacillus paracasei A21151 with blood uric acid reducing and anti-inflammatory effects and application thereof |
| CN117025456B (en) * | 2023-07-31 | 2024-02-06 | 广西爱生生命科技有限公司 | Lactobacillus paracasei A21151 with blood uric acid reducing and anti-inflammatory effects and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113293113B (en) | Bifidobacterium longum MI-186 and application thereof | |
| CN116254190A (en) | Lactobacillus paracasei subspecies and application thereof | |
| CN110184209B (en) | Lactobacillus rhamnosus capable of reducing blood uric acid | |
| CN114181864B (en) | Lactobacillus rhamnosus HF01 and application thereof | |
| CN112458007A (en) | Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder | |
| CN113234640A (en) | Bifidobacterium longum MF-269 and application thereof | |
| CN110747146A (en) | Lactobacillus gasseri LG08 with uric acid degradation effect and application thereof | |
| CN113897302B (en) | Bifidobacterium capable of relieving colitis and application thereof | |
| CN116024130B (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN110023484B (en) | Bifidobacterium pseudocatenulatum as well as culture method and application thereof | |
| CN114107121B (en) | Bacillus coagulans and application thereof in treatment of alcoholic liver disease | |
| CN114634901A (en) | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof | |
| CN113249280A (en) | Streptococcus thermophilus STN26, bacterium powder and application in uric acid reducing product | |
| CN113797232B (en) | Composition with insulin resistance relieving function and application thereof | |
| CN115786207A (en) | Lactobacillus salivarius and application thereof in preparation of medicines for treating and/or preventing diabetes | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN114774335B (en) | Bifidobacterium longum 070103 with effects of targeting glucokinase and remarkably reducing blood sugar and blood fat and application thereof | |
| CN111700918B (en) | Medicine for relieving alcoholic intestinal injury | |
| CN115029260A (en) | Lactobacillus gasseri with anti-inflammatory and antioxidant properties and application thereof | |
| CN111603490B (en) | Medicine for preventing and/or treating alcoholic intestinal injury | |
| CN117363524B (en) | Lactobacillus gasseri MY4 and application thereof in preparation of sleep-aiding and whitening medicines | |
| CN116590181B (en) | Lactobacillus paracasei for improving inflammatory reaction caused by microplastic pollution and application thereof | |
| CN117305187B (en) | Pediococcus acidilactici for improving intestinal health condition and application thereof | |
| CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof | |
| CN114806953A (en) | Lactobacillus gasseri with characteristic of improving type 1 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |